MAPT and early-onset autosomal dominant Alzheimer disease: Multiple classification schemes for staging of the disease have been developed, including neuropathological staging according to Braak and Braak [1], henceforth referred to as Braak stages, the CERAD stages (defined by the “Consortium to Establish a Registry for Alzheimer’s Disease”) based on neuritic plaque load [2], or the A/T/N scheme based on the three binarized biomarker categories (A) β-amyloid load, (T) tau biomarkers including phosphorylated tau (p-Tau), and (N) neurodegeneration markers [3].